期刊文献+

盐酸氨溴索应用剂量对非小细胞肺癌并发肺部感染患者炎症反应与肺脏功能水平影响的研究 被引量:3

Effects of Ambroxol Hydrochloride on Inflammatory Response and Lung Function Level in Patients with Non-Small Cell Lung Cancer Complicated by Pulmonary Infection
下载PDF
导出
摘要 目的:探究盐酸氨溴索应用剂量对非小细胞肺癌并发肺部感染患者炎症反应与肺脏功能水平影响。方法:选取2015年3月~2018年3月期间在某院接受治疗的非小细胞肺癌并发肺部感染患者84例,采取随机数表法将患者随机分成对照组和实验组。对照组在常规化痰、镇痛、营养支持治疗基础上给予常规剂量盐酸氨溴索注射液进行治疗,实验组在对照组治疗的基础上给予大剂量盐酸氨溴索注射液进行治疗,观察比较两组患者的治疗前、后的C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)、中性粒子细胞绝对计数(ANC)数据、血氧分压(PaO2)、二氧化碳分压(PaCO2)、酸碱度(pH)水平及肺活量数据。结果:治疗后两组患者的FVC(L)、FEV1/FVC的数据比较差异不具有统计学意义(P>0.05);实验组患者治疗前的CRP、TNF-α、ANC水平与对照组比较差异不具有统计学意义(P>0.05),治疗后实验组、对照组的CRP水平数据分别为(4.25±1.79)mg·L^-1、(9.04±2.71)mg·L^-1,实验组患者的CRP水平高于对照组,数据差异具有统计学意义(P<0.05)。结论:大剂量盐酸氨溴索在治疗非小细胞肺癌并发肺部感染患者中的效果显著,能够有效缓解患者的炎性反应,提升患者的肺脏功能水平,值得临床推广。 Objective:To explore the effect of ambroxol hydrochloride on inflammatory response and lung function in patients with non-small cell lung cancer complicated by pulmonary infection. Methods:A total of 84 patients with lung infection complicated with NSCLC who received treatment in a hospital from March 2015 to March 2018 were selected and randomly divided into control group and experimental group by random number table method. The control group was treated with conventional dose of ambroxol hydrochloride injection on the basis of conventional treatment of phlegm elimination, analgesia and nutrition support, while the experimental group was treated with high-dose ambroxol hydrochloride injection on the basis of treatment of the control group. C-reactive protein(CRP), tumor necrosis factor(TNF-α), neutral particle cell absolute count(ANC), blood oxygen partial pressure(PaO2), carbon dioxide partial pressure(PaCO2), pH level and lung capacity of the two groups of patients before and after treatment were observed and compared. Results: FVC(L) and FEV1/FVC were not significantly different between the two groups after treatment(P>0.05).There were no statistically significant differences in CRP, TNF-α, and ANC levels between the experimental group and the control group before treatment(P>0.05), but the CRP levels in the experimental group and control group were(4.25±1.79)mg·L^-1 and(9.04±2.71)mg·L^-1 after treatment, respec-tively.The CRP levels in the experimental group were higher than those in the control group,and the data differences were statistically significant(P <0.05).Conclusion:Ambroxol hydrochloride has a significant effect in the treatment of patients with lung infection complicated with non-small cell lung cancer,which can effectively relieve the inflammatory reaction of patients and improve the level of lung function of patients,and is worthy of clinical promotion.
作者 冯凌云 Feng Lingyun(Zhoukou Shenqiu County People's Hospital,Henan Province,Zhoukou 466300)
出处 《数理医药学杂志》 2020年第5期715-717,共3页 Journal of Mathematical Medicine
关键词 盐酸氨溴索 非小细胞肺癌 肺部感染 炎症反应 肺脏功能 ambroxol hydrochloride non-small cell lung cancer pulmonary infection inflammatory response lung function
  • 相关文献

参考文献4

二级参考文献45

  • 1Li Y, Burns JA, Cheney CA, et al. Distinct expression profiles of Notch-1 protein in human solid tumors : Implications for development of targeted therapeutic monoclonal antibodies [ J ]. Biologics, 2010,4 : 163-171.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA CancerJ Clin, 2012, 62(1):10-29.
  • 3Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11(6):521-529.
  • 4Mok TS, Wu YL, Yhongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma[J]. N EnglJ Med, 2009, 361 (10) :947-957.
  • 5Rosell R, Garcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as ftrst--line treatment for European patients with advanced EGFR mutation positive non- small- ceU lung cancer (EURTAG): a muhicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3):239-246.
  • 6Shi YK, Zhang L, Liu XOx et al. Icotinib versus gefitinib in previously treated advanced non-small-ceU lung cancer (ICOGEN): a ran- domized, doubleblind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10):953-961.
  • 7Miller VA, Hirsh V, CadranelJ, et al. Afafinib versus placebo for patients with advanced, metastatic non-smaU-cell lung cancer af- ter failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised tria[J]. Lancet Oncol, 2012, 13(5):528-538.
  • 8Janne PA, Ou SH, Kim DW, et al. Dacomitinib as ftrst-line treat- ment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialm. Lancet Oncol, 2014, 15(13):1433-1441.
  • 9Ramalingam SS, Janne PA, Mok T, et al. Dacomitinib versus erlo- tinib in patients with advancedstage, previously treated non- small-cell lung cancer (ARCHER 1009): a randomised, double- blind, phase 3 trial[}]. Lancet Oncol, 2014, 15(12):1369-1378.
  • 10Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemo- therapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase Ⅲ trial[l]. Lancet, 2009, 373(9674):1525-1531.

共引文献98

同被引文献30

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部